Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy.

Trial Profile

Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COG; HANDEL; TRANS-COG
  • Most Recent Events

    • 24 May 2017 Primary endpoint (Overall Survival in EGFR FISH (fluorescent in situ hybridization)-negative patients for TRANSCOG sub-study) has not been met, according to results published in the Journal of Clinical Oncology.
    • 24 May 2017 Primary endpoint (Overall Survival in EGFR FISH (fluorescent in situ hybridization)-positive patients for TRANSCOG sub-study) has been met, according to results published in the Journal of Clinical Oncology.
    • 24 May 2017 Results of TRANSCOG sub-study (n=340), published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top